Radiotherapy Combined With Intratumoral Injections of Dendritic Cells and Rituximab - a Phase II Cancer Vaccine Trial for Patients With Untreated and Relapsed Indolent Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2017
Price : $35 *
At a glance
- Drugs Dendritic cells (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms Lymvac-1
- 09 Sep 2017 Results of gene expression analysis from this study, presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
- 22 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Sep 2013 New trial record